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Abstract
The role of the corticotropin releasing hormone in the onset of labour and the subsequent medicinal
chemistry implications of CRH antagonists for the prevention of premature birth, and identification of
the CRH type 1 receptor as the target for this drug design, are reviewed here.

Introduction
Preterm labour is the outcome of 10% of all pregnancies and accounts for 70% of all neonatal
morbidity and mortality.1,2 Even though tocolytic and corticosteroid techniques have been used to
inhibit labour and reduce the consequences of prematurity on the foetus, they have not reduced the rate
of preterm birth.2,3,4
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Human parturition is characterised by a complex interplay of autocrine/paracrine signalling.5 One
such chemical in this interplay is corticotropin releasing hormone (CRH), a 41 amino acid peptide
originally isolated from ovine hypothalamus. It is the principle neuroregulator of the basal and stressinduced secretion of ACTH, β-endorphin, and other propiomelanocortin-related peptides from the
anterior pituitary. CRH is found in the hypothalamus, pituitary and placenta. Recently it has been found
that women who experience preterm labour have a higher concentration of plasma CRH compared to
gestationally matched women with full term pregnancies.6
The corticotropin releasing hormone as a drug design target for the medicinal chemist has attracted a
notable amount of attention with respect to the treatment of depression, anxiety and other
neuropsychiatric disorders.7,8,9 However, with the recent reporting of the importance of CRH in the
onset of labour and the ability of antagonists of the CRH type 1 receptors to delay the onset of labour in
sheep model studies,10,11 the development of CRH type 1 receptor antagonists as potential treatments
for premature birth have taken on a new direction and significance. We have recently reviewed the
status of CRH antagonists themselves and their medicinal chemistry implications within the field of
premature birth.12 Of great importance to drug design and development by the medicinal chemist is an
intimate knowledge of the targets involved. Here we review the interplay of CRH in labour
progression, and the status of the CRH type 1 receptor as a target for the treatment of premature birth,
through drug design and development of small ligand antagonists.
Premature Birth
Premature birth is defined by the World Health Organization as birth at less than 37 weeks of
completed gestation, full term as birth between 37 and 42 weeks of gestation.13 Premature birth affects
approximately 1 in 10 pregnancies and accounts for at least 75% of all neonatal mortalities, excluding
those related to congenital malformations.14 Infants born prematurely are 40 times more likely to die
during their first few weeks, and those that survive have an increased risk for developing morbidities
such as deafness, blindness, cerebral palsy, respiratory illness and other complications.15
A large-scale study carried out in the United Kingdom and Ireland of extremely premature infants, born
between 20 and 25 weeks of gestation, found that 79% were stillborn or died before admittance to a
Neonatal Intensive Care Unit (NICU).16 Of the 811 infants in this study admitted to an NICU, 60%
died in hospital. Of those discharged; 2% died, 23% were classified as having severe disability at 30
months (defined as one likely to put the child in need of physical assistance to perform daily activities),
25% had other disabilities at 30 months, and 49% were found to have no disabilities at 30 months. No
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relation between the pattern of morbidity and either gestational age or occurrence of multiple birth
was found.16
Over the past 30-40 years, there has been a substantial decrease in the rate of neonatal mortalities due
mainly to the development of neonatal intensive care units, yet no decrease in the rate of premature
birth itself. Neonatal survival has been shown to improve most significantly with gestational age, as
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Fig. (1): Neonatal survival (28 days of life) increases according to gestational age at birth. Data derived
from institutions in Britain, Europe, and Scandinavia.4
This increase in survival is accompanied by a dramatic increase in the cost of caring for these babies,
with neonatal care one of the most expensive items in health care budgets, in terms of cost per
patient.15 In the US alone, it has been estimated to cost $US 5 to 6 million annually.1 Medication and
therapy for a disabled child results in a constant financial burden and the need for special education
classes and additional resources to overcome learning difficulties can also contribute to the costs of
caring for children born prematurely.17
Even though survival of preterm infants has increased, there has not been a decrease in the rate of
premature birth in the last 30 years.15 This is mainly due to the lack of understanding of the underlying
mechanisms precipitating parturition and thus a lack of appropriate technologies for diagnosis and
treatment. Parturition involves structural and functional changes of the myometrial, cervical and foetal
membranes that are essential for labour and delivery to occur.18
Current Prevention
The current system of prevention is largely unsuccessful, as no accurate test exists to predict the early
onset of parturition. Current techniques rely on a screening program to identify those at high risk of
giving birth prematurely, modification of their specific determinants of risk, and, if necessary, drug
treatment. Tocolytic drug therapy is employed to delay labour, and corticosteroids are used to improve
foetal outcome by promoting organ maturation.15
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Risk scoring tests, such as the commonly used Creasy system, calculate a risk index for individual
pregnant women where socio-economic, medical history and lifestyle factors are weighted.15 Some
clinical factors associated with preterm labour are shown in Table 1.14 The sensitivity of such risk
tests, however, ranges between 25 and 50%, meaning that at least half of the women that give birth
prematurely would not be identified as having a high risk and thus not targeted for preventative
treatment.15
Table 1: Clinical factors associated with preterm labour

Maternal Factors

Low socio-economic status; Non-white race;
Maternal age ≤ 18 or ≥ 40 years; Smoking;
Low pregnancy weight; Substance abuse

Maternal History

Previous history of preterm delivery;
Previous history of a second-trimester abortion.

Uterine Factors

Uterine volume increased;
Uterine anomalies; Trauma.

Infection
Early identification of preterm risk is crucial to successful tocolytic therapy, with the effectiveness of
these agents reduced if labour has already been initiated.15 While the efficacy of tocolytic agents, such
as magnesium sulphate, ritodrine and terbutaline have long been debated, their use has been associated
with a delay of labour of 24 to 48 hours.14 A study by Guinn and associates (1998), found that
treatment of preterm women with terbutaline did not prolong gestation compared to those treated with
a placebo, even when it was administered by pump to allow continuous low dosing and instant
administration of medication when uterine contractions developed. Therapy also had to be aborted in
several cases due to the development of side effects.19
The many contraindications and side effects of tocolytic therapy limit their use for treatment of preterm
labour.14 Ritodrine, the most common drug used to delay preterm labour, is poorly tolerated and causes
maternal hypotension and significant maternal and foetal tachycardia.14
Delay of labour allows the administration of corticosteroids, which have been shown to improve foetal
outcome by reducing intraventricular haemorrhage, respiratory distress syndrome, and mortality, even
when therapy lasts less than 24 hours. Optimal benefits, however, begin after 24 hours of corticosteroid
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therapy and last a week.15 This, as well as the limitations to their use, highlights the need for tocolytic
agents that delay labour for a longer period. It should be noted that while the combined use of these
agents may improve foetal outcome, therapy with tocolytic and corticosteroids does not reduce the
incidence of preterm labour.14
Much research is currently being conducted into the usefulness of biological markers for the prediction
of preterm pregnancy, since hormones and other biological substances encounter concentration changes
during pregnancy, particularly at parturition.
Continued gestation is desirable for 30-45% of preterm pregnancies that result from spontaneous
idiopathic preterm labour. The development of agents to prevent preterm labour would be of most
benefit to these pregnancies. The other 55-70% of preterm pregnancies result from foetal or maternal
compromise, which makes the continuation of pregnancy undesirable.12
Corticotropin-Releasing Hormone (CRH)
Research into the mechanisms underlying human pregnancy have revealed that corticotropin-releasing
hormone (CRH) is a key signal and potential regulator for the onset of birth.18 It is produced in the
hypothalamus and placenta during pregnancy and has been implicated in a variety of central and
peripheral functions including behaviour, food intake, thermoregulation, inflammation, reproduction,
cardiovascular function, gastrointestinal secretion, motility, and transit.12,20
Corticotropin-releasing hormone (CRH) is a 41 amino acid peptide, Fig. (2),20,21,22 synthesised
primarily in the hypothalamus and then transported via the portal system to the anterior pituitary,
where it regulates the release of adrenocorticotropin (ACTH)20, β-endorphin and other
propiomelanocortin-derived peptides.23 These peptides are released from the anterior pituitary gland
into the general circulation and work primarily by binding to the CRH receptor.24 ACTH stimulates
secretion of glucocorticoids from the adrenal gland and is the principle regulator of the hypothalamicpituitary axis (HPA).25
H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu
-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu
-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln
-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile
-Ala-NH2

Fig. (2): The amino acid sequence of CRH.21
CRH forms a secondary structure α-helical amphipathic molecule in solution and on binding to the
receptor.20,22 The first 8 residues are important for activation, whereas the hydrophobic side chains
from amino acids 15-19 are crucial for activation of the receptor as well as its binding, the remainder of
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the C terminus is involved in binding and is required in its entirety for full potency.20 The C-terminal
region is responsible for the formation of the α-helix.20 For further details on the secondary structure of
CRH see previous review.12
Hypersecretion of CRH in the brain is associated with depression, anxiety-related disorders, and
anorexia nervosa, whereas a deficit of CRH in the brain, due to dysfunction of CRH neurons, is
associated with Alzheimer’s disease,26,27 Parkinson’s disease,28 and Huntington’s disease.
Overproduction of CRH at synovial joints is thought to contribute to rheumatoid arthritis.28 It also
mediates other responses including inflammatory disorders such as rheumatoid arthritis,29 food
intake,30 thermoregulation, various behavioural responses, cardiovascular function,21 stroke, tumours
and from an ectopic centre, Cushing’s syndrome.29
CRH has also been discovered in extra-hypothalamic sites such as the human placenta.31 Hypothalamic
and placental CRH are identical in structure and bioactivity, but differ in their regulation.
Glucocorticoids inhibit the production of hypothalamic CRH but stimulate the production of placental
CRH, establishing a positive feedback loop during pregnancy that results in elevated levels of CRH,
ACTH and cortisol, a glucocorticoid important for foetal lung maturation.32 The secretion of placental
CRH is also stimulated by prostaglandins, cytokines and catecholamines and inhibited by nitric
oxide.18
The processing of CRH from its precursor also differs in the hypothalamus and placenta. Like most
hormones, CRH is synthesised from a pro-hormone, pro-CRH, and released post-translation by the
action of endopeptidases. After signal peptide removal and C-terminal amidation to yield pro-CRH27194,

endoproteolytic cleavage at two sites (between pairs of basic amino acids at residues 124-125 and

151-152) produces three products: the N-terminal product, CRH27-124; the mid-portion fragment; proCRH125-151; and C-terminal CRH1-41.33 In the hypothalamus, pro-CRH undergoes immediate posttranslational processing with subsequent storage of mature CRH1-41. In the placenta, however, most
CRH exists as unprocessed pro-CRH, with very little in the form of mature CRH1-41, except in preeclampsia,33 a complication of pregnancy characterised by hypertension and proteinuria.
CRH Receptors
CRH binds to the CRH receptor family, consisting of a seven transmembrane domain receptor Fig
(3).23,24 The two main receptor isoforms, CRH1 and CRH2, are part of the class II (secretin-type) Gprotein coupled receptor (GPCR) super family.26,34 When the CRH ligand binds to the CRH1 or CRH2
receptor, the signal is activated and conducted via a Gs-coupled,34 adenylate cyclase second messenger
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system.27 This messenger system is present in brain, pituitary and spleen tissue.35 Treatment of
placental and foetal tissues with CRH does not activate adenylate cyclase but does increase inositol
phosphates (IP3, IP2, IP) suggesting that CRH receptors can couple to different G proteins in different
tissues.36
The N-terminus contains the sequence responsible for high affinity binding of the agonist and
antagonist.34 The CRH receptor has five predicted glycosylation sites at the N-terminus whose function
are currently unknown, Fig (3).27,34 The C-terminus appears to be needed for G-protein activation even
though the G-protein is coupled to the residues in the first intracellular loop. CRH receptors are down
regulated upon continual exposure to CRH due to phosphorylation state of the C-terminal cytoplasmic
tail serine/theronine domain, which may regulate the internalization of the CRH antagonist.34 Both
CRH1 and CRH2 receptors are serine/threonine rich (CRH1: AA 396-413) and contain potential
protein Kinase A/C phosphorylation sites in the 1st loop and the carboxyterminus tail, Fig (3).27

Fig. (3): The amino acid sequence of corticotropin releasing hormone CRH1, CRH2α and CRH2β
receptors. The receptor is shown with the seven predicted transmembrane domains. The main receptor
shown is CRH1 and the arrows indicate where CRH2α and CRH2β diverge at the N- terminus (shown in
red and purple respectively). Amino acids that are shaded in green are those that differ between CRH1
and CRH2 receptors. Potential N-glycosylation sites are marked by ψ and potential sites of protein
kinase C phosphorylation are denoted by ▲. Figure adapted from reference 26.

The CRH1 receptor is made up of 415 amino acids, Fig. (3).27,34 CRH1 is primarily found in the
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cerebellum, cerebral cortex,21 and sensory relay structures as well as localisation in placental and foetal
tissue.27 Within the pituitary gland CRH1 is found in both anterior and intermediate areas and is
believed to be responsible for regulation of ACTH levels.27
The CRH2 receptor sub-family has a different sequence, tissue distribution and pharmacological profile
to the CRH1 receptor but has high structural homology to the CRH1 receptor.24,27 These receptors are
mainly localised in the sub cortical structures.27 CRH has a lower affinity for CRH2 receptors than
CRH1.21
There are three spliced variants of the CRH2 receptor. These isoforms are the CRH2α, CRH2β and
CRH2γ receptors. The CRH2α receptor is a 411 amino acid protein21 and is 71% homologous to the
CRH1 receptor but has a different N-terminal sequence,27 which is involved in the ligand-receptor
interaction.37 In humans CRH2α is predominantly expressed in the hippocampus, heart, skeletal muscle,
hypothalamus, septum and cortex.37 CRH2β is a 431 amino acid protein that differs from CRH2α at the
N terminus.21 It is found mainly in rat heart, lung and sketetal muscle aswell as having limited
distribution in the septum, hippocampus and amygdala.38
The third isoform of the CRH2 receptor is CRH2γ.37 CRH2γ is expressed in the central nervous system
(CNS) in a similar pattern to CRH2β but follows the pharmacology of the CRH2α receptor.37 CRH2γ is
mainly expressed in the septum and hippocampus and weakly in the amygdala. CRH2γ is weakly
detectable in the lung but absent in the heart and skeletal muscle.37 The lack of overlap in the tissue
localisation of CRH1, CRH2α and CRH2β suggests a distinctive functional role for each receptor.21,27
However, the role different receptors may play in illness is still undergoing investigation and intensive
research.24,26
CRH binding protein (CRH-BP) is a 322 amino acid protein,40 with a MW of 37kDa.41 It is produced
by the liver, placenta and brain.41 CRH-BP has a large influence on the bioactivity of CRH and seems
to protect the anterior pituitary gland, but not the hypothalamus, from over stimulation by excess
concentrations of placental CRH.23,41,42 It circulates in the plasma, binding excess hormone,
particularly during pregnancy when placental CRH is secreted into maternal and foetal plasma. When
the CRH-BP complex is formed it is subject to rapid clearance from the blood,43 more rapid than other
glycoproteins its size.42
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Concentrations of both CRH1 receptors in reproductive tissues36,44 and circulating CRH-BP,27 change
during pregnancy and labour, thus providing further support to the theory that CRH has an important
role in gestation and birth.
CRH - A Role in Pregnancy
Placental CRH is secreted into both the maternal and foetal circulations, in a 10:1 ratio.12 Studies have
shown that the concentration of placental CRH secreted into the maternal plasma increases
exponentially during pregnancy, climaxing at birth, Fig. (4). Human CRH levels are normally less than
2 pmols, but during pregnancy may exceed 10 times this level.45 Concentrations of CRH are maintained
during pregnancy by CRH-BP, which binds CRH with high affinity. The level of this binding protein
decreases at approximately 36 weeks of gestation resulting in a dramatic increase in maternal plasma
CRH leading to the onset of structural and functional changes in gestational tissues, in preparation for
parturition.18 CRH-BP levels return to non-pregnant levels within 5 days postpartum.23
CRH is secreted from the syncytiotrophoblast and intermediate trophoblast layer of the placenta during
pregnancy.41,46 It is also secreted from the epithelium and subepithelial cells of the amnion and the
amniotic epithelium of the umbilical cord.29
4000
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Fig. (4): Comparison of the molar concentrations of CRH and CRH-BP in maternal plasma during the
final 180 days of gestation in pregnancies ending in spontaneous labour.17

As pregnancy progresses into the second trimester, CRH increases exponentially towards term,47 rises
dramatically during labour23 and declines quickly following parturition.29 This rise in CRH blood
plasma levels is mirrored in the amniotic fluid.29
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There is an extensive network of CRH receptors in the myometrium and these receptors are up
regulated to a high affinity receptor in the pregnant myometrium.48 A simplistic diagram showing the
major physiological effects of CRH is shown in Fig. (5). During most of pregnancy, the smooth muscle
of the uterus remains relaxed while the cervix, kept firm by collagen fibres, seals the bottom of the
uterus. Progesterone, a placental steroid hormone secreted into the maternal plasma, maintains this
structure of the uterine and cervical tissues.10 Oestrogen, another placental hormone, opposes these
effects and promotes contractility by stimulating the production of contractile agents and expression of
specific receptors and gap junctions during parturition. The production of oestrogen in the placenta is,
however, reliant on the ability of CRH to stimulate production of its precursor, dehydroepiandrosterone
sulphate (DHEA-S).10 Progesterone inhibits the activity of CRH, presumably by prohibiting the
propagation of the positive feedback loop that exists between CRH, ACTH, and cortisol.4
FOETUS

PLACENTA

CRH

CRH

ACTH

DHEA-S

MOTHER

Myometrial
Contraction

DHEA-S

Oestrogen

Oxytocin

CRH

Cervical
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Cortisol
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Lung
Maturation

Prostaglandins

Collagen
Enzymes

Fig. (5): Corticotropin releasing hormones role in parturition.10,47

The absence of progesterone receptors in the placenta means progesterone must compete for
glucocorticoid receptors. Progesterone binds with a higher affinity to these receptors, effectively
inhibiting cortisol binding and propagation of the feedback loop, thus inhibiting CRH secretion.49 It is
believed however that secretion of placental CRH into the foetal circulation allows propagation of the
feedback loop in the foetus. Accumulation of cortisol would produce effective concentrations that
would displace progesterone from placental glucocorticoid receptors, counteracting its actions and
stimulating CRH secretion. The establishment of the positive feedback loop in the placenta, and a
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significant drop in circulating CRH-BP, results in the exponential increase of CRH seen in maternal
and foetal plasma in the later stages of gestation.49
Foetal cortisol production is then responsible for foetal lung maturation in preparation for birth.10
Placental CRH and foetal ACTH stimulate the production of DHEA-S which is then converted to
oestrogen in the placenta. Oestrogen stimulates the production of prostaglandins F2α and E2, which in
turn maintain CRH synthesis in the placenta,50 as well as enzymes that digest collagen fibres,
promoting dilation of the cervix. Oestrogen also stimulates the formation of gap junctions between
myometrial (uterine muscle) cells, which allows coordination of contractions, and increased expression
of oxytocin receptors in the myometrium. Oxytocin is a maternal steroid hormone that stimulates
myometrial contraction.50 A positive feedback loop results with continued secretion of oxytocin until
contractions are strong and close enough to lead to birth.10 The action of this hormone, as well as that
of prostaglandins, is potentiated in the presence of CRH but CRH has no contractile activity of its
own.50
CRH is also a potent vasodilator, producing hypotensive effects, and is thought to have an important
role in the regulation of foetal-placental vascular tone. Increased CRH production is a possible
compensatory response to increased placental vascular resistance.51 This is associated with impaired
availability of oxygen and endogenous substrate, restriction of foetal growth and subsequently high
perinatal mortality.23
Elevated levels of CRH can be neurotoxic to parts of the brain responsible for learning and memory,
resulting in impaired foetal responsiveness to novel stimulus. These regions of the brain are also rich in
CRH receptors, suggesting a role for CRH in foetal neurological development.52
Rodent placenta does not produce CRH and CRH does not affect parturition in these animals. Foetal
rodents do synthesize CRH in localised brain areas as well as express CRH1 and CRH2 receptors in late
gestation, indicating that the foetal nervous system is a plausible target for extra-hypothalamic CRH.
Administration of CRH to pregnant rodents results in infants with developmental anomalies.52
Low concentrations of CRH have been associated with development of depression and antisocial
behaviour during pregnancy, particularly in pregnant adolescents.53,54 It is suspected that reduced
sensitivity and expression of CRH receptors during the postpartum period, due to hyperactivity of the
HPA axis by placental CRH during pregnancy, may persist postpartum and reduce adrenal
allopregnanolone synthesis. Allopregnanolone, a derivative of progesterone, induces anxiolytic,
hypnotic, and anticonvulsant effects upon systemic administration. Such neurosteroids have been
linked to modification of neuronal excitability, mood, and adaption to stress. Levels of
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allopregnanolone are significantly decreased in women with maternity ‘blues’, the mildest form of
depression, postnatal depression being more serious.54 The 40-70% of postpartum women who develop
maternal blues, are four times more likely to develop postnatal depression. Allopregnanolone levels are
also significantly reduced in women with premenstrual syndrome.
Premature Labour and CRH
Cross-sectional studies have revealed that the concentrations of placental CRH in maternal plasma are
elevated in women who have delivered preterm, Fig. (6).18
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Fig. (6): Non-logarithmic representation of the three regression curves demonstrating the exponential
increase of plasma CRH with advancing gestation.17
This regulation of the length of pregnancy by CRH has been termed a ‘placental clock’.18 Differences
in maternal CRH concentrations are significant at approximately 20 weeks of gestation,18 with the most
significant elevation of CRH seen in high risk populations that deliver before 34 weeks.55 The
significance of this finding has not gone unnoticed, with much interest in the use of maternal CRH
concentrations as a biological marker.
Interest has also been directed towards the use of CRH as a drug target. The presence of CRH and its
receptors in reproductive tissues supports a functional role for CRH in gestation, as does the elevated
levels of maternal plasma CRH during this period. It is believed that antagonism of CRH would
appropriately delay labour in women destined to deliver prematurely. Antagonism of CRH1 receptor in
sheep has been shown to delay the onset of parturition.56
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CRH1 Receptor Antagonism
Structure-activity relationship (SAR) studies of the corticotropin-releasing hormone peptide revealed
that residues 1-4 are not necessary for receptor binding or transduction, residues 4-8 are important for
activation, and residues 12-41 are mainly responsible for binding.20 A further SAR study, utilising an
alanine replacement series of ovine CRH, found that the side chains of residues 5-19, in the N-terminal
region, are important for receptor binding and activation.22 C-Terminal amino acid residues are more
responsible for structural conservation than for functional expression. The α-helix formed by CRH
upon binding is highly amphiphilic in nature with hydrophobic and hydrophilic regions segregated on
opposite faces of the helix.22

Cleavage of the first eight to fourteen residues of CRH produces antagonists of varying potency to
CRH, such as α-helical CRH9-41.57 Structural stabilisation of these antagonists, using D-amino acid
residues to stabilise β turns, i-(i+3) Glu-Lys and Lys-Glu salt bridges or β-lactam rings to stabilise the
α-helical structure, has also been shown to increase the potency of some of these agents.58,59 Astressin
{cyclo(30-33)[D-Phe12,Nle21,38,Glu30,Lys33] rat/human CRH(12-41)}, a potent CRH antagonist has a
tertiary structure stabilised by the presence of D-isomers and a i-(i+3) salt bridge.60 The introduction of
this salt bridge to astressins parent compound, [D-Phe12,Nle21,38] r/hCRH(12-41), increases the potency
of this molecule 30 fold. Astressin has a Ki of 2 nM and high affinity for CRH pituitary receptors.58
These peptide antagonists have been shown to suffer from limited solubility, persistence of intrinsic
activity and weak potency at the hypophyseal site of action.58 The low bioavailability of peptide agents
makes these antagonists of little therapeutic use, although they have been important in the investigation
of CRH function and binding.
Recently, there have been large numbers of non-peptide low-molecular weight ligands emerging as
CRH1 antagonists. These antagonists have significant advantage over peptide molecules as they may be
orally administered, have a longer duration of action and have activity within the CNS.61
The current CRH1 receptor antagonists have been designed for use in depression and anxiety related
disorders. These all have a similar core structure consisting of a nitrogen containing, aromatic unit (for
example, a pyrimidine, triazine or purine group), linked to a substituted anilino moiety.28 Examples of
these types of compounds are shown in Fig. (7). Numerous high affinity ligands have been developed
in the pyrrolo-pyrimidine series of compounds, but attempts to increase the hydrophilicity of these
compounds has resulted in a reduction in binding affinity.62
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Fig. (7): CRH1 antagonists. (a) Pyrimidine structure antagonist with a binding affinity of 2.3 nM (Ki).
(b) Triazine analogue with a Ki of 57 nM. (c) Conformationally restricted purine based CRH1
antagonist CP-154,256 Ki of 2.7 nM. (d) Antalarmin Ki of 1.7 nM.38
Various derivatives of these types of structures have been made with the major variations being of the
aliphatic substituents on the aryl ring, central heterocycle and the tertiary amino group.12 Structure
activity relationship (SAR) analysis of these derivatives has revealed that the anilino substituent should
be either 2,4 or 2,4,6 substituted with medium sized lipophilic or weakly H-bonding groups, generally
these are halogens or methyl substituents.12 The nitrogen ortho to the anilino substituent is essential for
activity and optimal activity is incurred with a teriary amine on the heterocyclic ring attached to two
lipophilic chains with chain lengths no longer than 3 and 5 carbons respectively, Fig. (8). Recent SAR
studies have also suggested that the tertiary amine can be replaced with alkyl ether substituents whilst
retaining activity.62
lipophilic group
max. chain length
5 carbons

lipophilic group
max. chain length
3 carbons
N

optimal Me

N
nitrogen essential
optimal H,
OMe or SMe
(a)

small alkyl
groups

N
N

medium sized groups,
halogen or CH3S optimal
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Fig. (8): (a) Structure activity relationship (SAR) study of CRH1 antagonists. (b) Pharmacophore
generated using a range of CRH1 antagonists shown with the compound shown in Fig. (7a) overlayed.
Hydrophobic regions are highlighted by spheres (bottom and top right); spheres (centre right) represent
π-stacking interactions; hydrogen bond acceptors are represented by spheres (left) with the projected
interactions illustrated by a cone.
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A pharmacophore model was generated from a range of CRH1 antagonists, Fig. (8b). From this
model it can be seen that the heterocyclic nitrogen ortho to the anilino ring is involved in a hydrogen
bonding interaction, the anilino ring itself is involved in a π-stacking interaction. There are also a
number of hydrophobic interactions, notably involving one of the tertiary amino substituents and the 2
and 4 substituents on the anilino ring. This shows high correlation to the SAR model, lacking only the
additional tertiary amino substituent and the methyl group on the heterocyclic ring Fig. (8a).
Two of the most active CRH1 antagonists to date are CP-154,256, Fig. (7c), and antalarmin Fig. (7d)
which has been shown to delay the onset of labour for one week in sheep.56 To achieve this inhibition,
the antalarmin was administered via infusion directly into the foetus over a 10 day period, using a 1:1
mixture of ethanol and polyethoxylated castor oil as a vehicle.56 This inhibition supported the
hypothesis of the potential use of CRH1 antagonists at potential therapies for the prevention of preterm
labour.
Conclusion
The design and synthesis of antagonists of the CRH family of receptors still requires significant
improvement before a suitable therapeutic can be developed. Intimate knowledge of the receptor sites
and potential modes of actions of different ligands provides valuable insight into this development, in
particular with respect to therapeutics for the prevention of premature birth. While much about these
receptors is still unknown, the emergence of new information will greatly benefit the development of
new CRH receptor antagonists.
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